Log in
Donate
Search
Close this search box.

Clinical Trial: NRG GY014

NRG GY014

Status: Closed

NCT#03348631

A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma

NRG GY014 is closed to accrual, effective June 15, 2022.

View All Clinical Trials
The Montana Cancer Consortium (MCC) is an independent nonprofit organization whose mission is to bring state-of-the-art cancer care to Montana, Idaho and Wyoming through National Cancer Institute (NCI) sponsored clinical research.

Navigation

About Us

Contact Us

Copyright © Montana Cancer Consortium | All rights reserved